All In Biotech

Drug Trial Radar · NCT02813135

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

472

Planned (sponsor's estimate)

Start

Aug 3, 2016

Primary completion

Feb 2031

Study completion Feb 2031

Sponsor

Lead sponsor
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute, France; Fight Kids Cancer; Fondation ARC
First posted
Jun 24, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This proof-of-concept platform trial is designed to cover the targeting of several survival pathways in oncogenesis that are currently not adequately employed for pediatric patients in Europe (Geoerger 2017; Geoerger 2019). The aims of the trial are: 1. To determine the recommended phase II dose (RP2D) of a specific anticancer agent and/or a relevant combination in a pediatric population, to document its tolerability and 2. To explore first signals of activity in a molecularly enriched study population.

Conditions

  • Pediatric Cancer

Interventions

  • RibociclibDrug

  • TopotecanDrug

  • TemozolomideDrug

  • EverolimusDrug

  • AdavosertibDrug

  • CarboplatinDrug

  • OlaparibDrug

  • IrinotecanDrug

  • VistusertibDrug

  • NivolumabDrug

  • CyclophosphamideDrug

  • SelumetinibDrug

  • EnasidenibDrug

  • LirilumabDrug

  • FadraciclibDrug

  • CytarabineDrug

  • DexamethasoneDrug

  • CeralasertibDrug

  • FutibatinibDrug

  • CapmatinibDrug

  • AvelumabDrug

  • PeposertibDrug

  • CapivasertibDrug

  • VinorelbineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended phase II dose (RP2D)Time frame: During the first cycle
  2. Maximum Tolerated Dose (MTD)Time frame: During the first cycle
  3. Objective Response Rate (ORR)Time frame: During treatment period

Locations

23 sites in 6 countries. Site status is shown where the registry gives one.

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • CHU Angers

    Angers, France · Recruiting

  • CHU Pellegrin

    Bordeaux, France · Recruiting

  • Centre Oscar Lambret

    Lille, France · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Hôpital de La Timone

    Marseille, France · Recruiting

  • CHU Nantes

    Nantes, France · Recruiting

  • Institut Curie

    Paris, France · Recruiting

  • Hôpital Armand Trousseau

    Paris, France · Recruiting

  • Hôpital de Hautepierre

    Strasbourg, France · Recruiting

  • Gustave Roussy

    Villejuif, Val de Marne, France · Recruiting

  • Istituto Giannina Gaslini

    Genova, Italy · Recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy · Recruiting

  • Ospedale Infantile Regina Margherita

    Torino, Italy · Recruiting

  • Prinses Maxima Centrum

    Utrecht, Netherlands · Active not recruiting

  • Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital del Nino Jesus

    Madrid, Spain · Recruiting

  • Hospital Universitario La Fe

    Valencia, Spain · Recruiting

  • Birmingham Children's Hospital

    Birmingham, United Kingdom · Recruiting

  • Great Ormond Street Hospital

    London, United Kingdom · Recruiting

  • Royal Manchester Children's Hospital

    Manchester, United Kingdom · Recruiting

  • Royal Victoria Infirmary

    Newcastle, United Kingdom · Recruiting

  • Pediatric and Adolescent Oncology The Royal Marsden Hospital

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.